PD19-12 PATIENT REPORTED OUTCOME MEASURES FOLLOWING HYPERBARIC OXYGEN THERAPY FOR RADIATION CYSTITIS

Abstract

You have accessJournal of UrologyCME1 Apr 2023PD19-12 PATIENT REPORTED OUTCOME MEASURES FOLLOWING HYPERBARIC OXYGEN THERAPY FOR RADIATION CYSTITIS Rachel A. Moses, Alexandra Hunter, Eileen R. Brandes, Devin R. Cowan, Nicole P. Harlan, Judy R. Rees, Kevin R. Krughoff, William Bihrle, and Jay C. Buckey Rachel A. MosesRachel A. Moses More articles by this author , Alexandra HunterAlexandra Hunter More articles by this author , Eileen R. BrandesEileen R. Brandes More articles by this author , Devin R. CowanDevin R. Cowan More articles by this author , Nicole P. HarlanNicole P. Harlan More articles by this author , Judy R. ReesJudy R. Rees More articles by this author , Kevin R. KrughoffKevin R. Krughoff More articles by this author , William BihrleWilliam Bihrle More articles by this author , and Jay C. BuckeyJay C. Buckey More articles by this author View All Author Informationhttps://doi.org/10.1097/JU.0000000000003285.12AboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareFacebookLinked InTwitterEmail Abstract INTRODUCTION AND OBJECTIVE: Prior studies demonstrate reduced bladder bleeding interventions after hyperbaric oxygen therapy (HBOT) for hemorrhagic radiation cystitis. Previously, we demonstrated feasibility of collecting urine-related patient reported outcome measures (PROMs) via the Multicenter Registry for HBOT. The purpose of this study is to evaluate change in urine related PROMs before and after HBOT in a larger, updated cohort. METHODS: Prospectively collected data from 19 sites in the Multicenter Registry for Hyperbaric Oxygen Therapy Consortium were analyzed. Measures included a hematuria scale adapted from the Radiation Therapy Oncology Group (RTOG) radiation cystitis scale and the Urinary Distress Inventory (UDI). Data obtained on the first and last days of HBOT were compared using the Wilcoxon rank sum test. RESULTS: 216 patients were included, 197 had complete RTOG/EROTC hematuria data, 146 had UDI data and 133 had both. Patients were on average 72 (+/-10.3) years old, 58/216 were diabetic, 81/216 were current or former smokers, and 187/216 developed radiation cystitis due to prostate cancer related radiation treatment. Referral for HBOT occurred approximately 7.0+/-5.8yrs following radiation. The average number of treatments was 36+/-11. RTOG/EROTC hematuria scores were significantly improved post HBOT (2.2 pre vs 0.9 post, p=0.001) (Figure 1A). UDI scores were significantly improved, post HBOT (61.5+/-31.5 pre vs 49.1+/-30.9, p<0.01) (Figure 1B). CONCLUSIONS: In a novel, multi-institutional prospective data set, we demonstrate HBOT is associated with improved urine related PROMs for individuals undergoing HBOT for radiation cystitis. Continued expansion of the registry may provide more generalizable results and allow for analysis of factors leading to change in UDI and hematuria scores. Source of Funding: N/A © 2023 by American Urological Association Education and Research, Inc.FiguresReferencesRelatedDetails Volume 209Issue Supplement 4April 2023Page: e582 Advertisement Copyright & Permissions© 2023 by American Urological Association Education and Research, Inc.MetricsAuthor Information Rachel A. Moses More articles by this author Alexandra Hunter More articles by this author Eileen R. Brandes More articles by this author Devin R. Cowan More articles by this author Nicole P. Harlan More articles by this author Judy R. Rees More articles by this author Kevin R. Krughoff More articles by this author William Bihrle More articles by this author Jay C. Buckey More articles by this author Expand All Advertisement PDF downloadLoading ...